Latest Conference Articles

September 23rd 2022, 9:00pm

American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting

Eplontersen treatment resulted in a significant reduction in transthyretin, neuropathy impairment, and improvement in quality of life in the phase 3 NEURO-TTRansform study of patients with hereditary transthyretin amyloidosis.

September 23rd 2022, 4:00pm

American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting

Minimal symptom expression, demonstrated by scores of 0 to 1 on MG-ADL, was observed in more than 25% of both rozanolixizumab groups compared with 3.0% of those on placebo.

September 23rd 2022, 3:00pm

American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting

The chief development officer at Clene Nanomedicine provided insight on the mechanistic function of CNM-Au8 and how it improves survival in patients with ALS. [WATCH TIME: 3 minutes]

September 23rd 2022, 1:00pm

American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting

Investigators concluded that those receiving avalglucosidase alfa should be tested for antidrug antibodies by physicians who treat Pompe disease and monitor antidrug antibody, according to a recent Sanofi investigation.

September 22nd 2022, 7:00pm

American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting

ADAPT+ study data on antiacetylcholine receptor antibody-negative patients with generalized myasthenia gravis found improvements in cycle baseline and efficacy with Efgartigimod.

September 22nd 2022, 7:00pm

American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting

The associate professor at the University of Michigan provided insight on new guidelines to treat painful diabetic neuropathy. [WATCH TIME: 2 minutes]

September 22nd 2022, 4:00pm

American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting

From the pre-COVID period to 6 weeks after vaccination, the reporting rate of GBS was significantly different, regardless of whether Brighton criteria was applied to the analysis. The authors noted that passive surveillance limitations warrant further analysis.

September 22nd 2022, 11:00am

American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting

Results from phase 2 RESCUE-ALS trial show that treatment with CNM-Au8 in ALS demonstrated improvement in survival compared to the estimated median survival rate.

September 21st 2022, 9:00pm

American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting

The phase 3 study, paused at US sites by the FDA, seeks to enroll 154 individuals with generalized myasthenia gravis, both seropositive and seronegative.

September 21st 2022, 7:00pm

American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting

After 12 weeks of treatment with zilucoplan 0.3 mg/kg, almost three-fourths of patients demonstrated at least a 3-point reduction in Myasthenia Gravis Activities of Daily Living scores.